シムラノドは,第2世代のニトロキシルドナーで,心不全でエジェクションフラクションの減少:血液動力学的有効性と安全性プロファイルのメタ分析
Mrunalini Dandamudi1, Vinh Q T Ho2, Miguel A Samaniego-Laguna3
1Montefiore Einstein Medical Center, 111 E 210th St, Bronx, NY, 10467, USA. mdandamudi@montefiore.org.
まとめ
シムラノドは,エジェクション分数が減少した患者の死亡率や主要な心不全指標を改善しませんでした. この薬は症状性低血圧のリスクを増加させ,現在,日常的な使用は推奨されていないことを示唆しています.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 心不全 (HF) は,世界的な健康上の大きな課題となっています.
- シムラノドのようなニトロキシル (HNO) ドナーは,血管拡張性特性により,HF治療の可能性を示しています.
研究 の 目的:
- シムラノドの安全性,耐受性,および血動力学的な影響を,心不全の患者およびエジェクション分数減少 (HFrEF) の患者で評価する.
主な方法:
- 459人の患者 (278人がシムラノドで,181人がプラセボで) を含む4つの研究のメタ分析.
- 死亡率,有害事象,および血液動力学的測定を含む評価されたアウトカム.
- コクラン方法を用いて評価された研究の品質;PROSPERO.に登録されたプロトコル.
主要な成果:
- シムラノドは,プラセボと比較して,全因死亡率,心臓死,または有害事象を有意に減少させませんでした.
- 症状性低血圧リスクの有意な増加が観察されました (RR=2.22).
- シストリック血圧の有意な低下は,Cimlanodの最高用量で観察されました.
結論:
- シムラノドは,HFrEF患者における死亡率または主要血液動力学的エンドポイントの改善に有効性を示しませんでした.
- この薬は,症状性低血圧のリスクを増加させた.
- 現在の証拠は,日常的なシムラノドの使用を支持していません;特定のサブグループについてさらなる研究が必要です.
関連する概念動画
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
01:22Heart Failure VI: Adjunct Therapies
399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
363
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
363